MetaVia Doses the First Patient in Higher-Dose Phase 1 Study of DA-1726, Its GLP-1 and Glucagon Dual Agonist for the Treatment of Obesity
Rhea-AI Summary
MetaVia (Nasdaq: MTVA) dosed the first patient in Part 3 of its Phase 1 trial of DA-1726, a dual GLP-1/glucagon oxyntomodulin analog for obesity. Part 3 tests one-step (to 48 mg) and two-step (to 64 mg) 16-week titration cohorts with 40 total subjects.
Company-reported early data include ~9% weight loss at 48 mg, waist circumference reductions, improved glycemic control, and early liver benefit signals; topline Part 3 data are expected in Q4 2026.
AI-generated analysis. Not financial advice.
Positive
- ~9% weight loss observed at the 48 mg dose
- Waist circumference reductions and improved glycemic control reported
- Early signals of direct liver benefit
- Part 3 designed to test higher therapeutic doses (48 mg and 64 mg)
- 16-week cohorts may enable a more streamlined titration versus competitors
Negative
- Small Phase 1 Part 3 cohort: 40 subjects total
- Topline Part 3 results not available until Q4 2026
News Market Reaction – MTVA
On the day this news was published, MTVA gained 18.49%, reflecting a significant positive market reaction. Argus tracked a peak move of +18.5% during that session. Our momentum scanner triggered 13 alerts that day, indicating notable trading interest and price volatility. This price movement added approximately $1M to the company's valuation, bringing the market cap to $7.41M at that time. Trading volume was very high at 4.0x the daily average, suggesting strong buying interest.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
MTVA was down 3.25% while peers showed mixed moves: declines in LPCN (-2.34%), PRTG (-10.39%), PULM (-0.87%) and gains in THAR (+5.8%), SYBX (+2.88%). This points to stock-specific trading rather than a sector-wide move.
Previous Clinical trial Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Mar 18 | IRB trial approval | Positive | -2.6% | IRB clearance for Phase 1 Part 3 higher-dose DA-1726 obesity study. |
| Jan 5 | Phase 1b results | Positive | -8.7% | Positive Phase 1b DA-1726 data with strong weight loss and liver benefits. |
| Aug 6 | Phase 1 extension | Positive | +2.9% | Extension of 48 mg MAD DA-1726 cohort to 8 weeks for added efficacy data. |
| Jul 9 | 48 mg cohort dosing | Positive | +8.2% | First patient dosed in 48 mg MAD cohort exploring maximum tolerated dose. |
| Jun 21 | Preclinical combo data | Positive | -0.9% | Preclinical DA-1241 combo data showing enhanced hepatoprotective effects in MASH. |
Clinical-trial news for MTVA has often seen muted or negative next-day reactions, with 3 of the last 5 such releases selling off despite generally positive data and an average move of about -0.21%.
Over the past year, MetaVia has steadily advanced its cardiometabolic pipeline. Multiple clinical updates on DA-1726 moved from initial 48 mg dosing to an extended 8-week MAD cohort and then to positive Phase 1b results with robust weight loss and metabolic benefits. Additional clinical work included preclinical combination data for DA-1241 in MASH. More recently, IRB approval cleared the way for Part 3 titration studies that the current announcement advances by dosing the first higher-dose patient, continuing the same Phase 1 program.
Historical Comparison
Clinical-trial headlines for MTVA have averaged a modest -0.21% move, so today’s -3.25% decline is weaker than typical for similar DA-1726 updates.
Clinical updates trace a clear DA-1726 path: initial 32–48 mg cohorts, extended 48 mg MAD dosing, statistically significant Phase 1b efficacy, IRB approval for Part 3, and now first-patient dosing in higher-dose titration cohorts.
Market Pulse Summary
The stock surged +18.5% in the session following this news. A strong positive reaction aligns with the company’s steady DA-1726 progress, now reaching higher-dose Part 3 titration cohorts with prior ~9% weight loss at 48 mg. Historically, clinical-trial headlines averaged only about -0.21% next-day moves, so a large gain would mark a departure from past trading patterns. Investors have also recently seen resale registration for up to 936,846 shares and warrant-related capacity of about $30.6M, which could influence longer-term dynamics.
Key Terms
oxyntomodulin medical
GLP-1 medical
glucagon medical
pharmacokinetics (PK) medical
pharmacodynamics (PD) medical
treatment-emergent adverse events (TEAEs) medical
body mass index (BMI) medical
cardiometabolic medical
AI-generated analysis. Not financial advice.
16-Week Study Evaluates One-Step Dose Titration to 48 mg and Two-Step Dose Titration to 64 mg in Obese Otherwise Healthy Adults
"Dosing the first patient in these higher-dose cohorts is an exciting milestone that moves us closer to unlocking the full potential of DA-1726," stated Hyung Heon Kim, President and Chief Executive Officer of MetaVia. "We have already seen compelling results, including approximately
The Phase 1 Part 3 trial is expected to enroll a total of 40 obese, otherwise healthy adult subjects, across two parts, with 20 subjects per part, randomized 4:1 (16 active; 4 placebo). Part 3A is designed to evaluate a one-step titration regimen with 16 mg for 4 weeks followed by 48 mg for 12 weeks, while Part 3B will evaluate a two-step titration regimen with 16 mg for 4 weeks, 32 mg for 4 weeks, and 64 mg for 8 weeks. The study will assess safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of DA-1726. Primary endpoints include monitoring adverse events (AEs), serious adverse events (SAEs), treatment-emergent adverse events (TEAEs), and AEs leading to treatment discontinuation. Secondary and exploratory endpoints include PK profiling and evaluation of metabolic, glycemic, lipid, and body composition measures, including weight, waist circumference, and body mass index (BMI), and other cardiometabolic measures.
For more information on this clinical trial, please visit: www.clinicaltrials.gov NCT06252220.
About DA-1726
DA-1726 is a novel oxyntomodulin (OXM) analogue functioning as a GLP1R/GCGR dual agonist for the treatment of obesity and Metabolic Dysfunction-Associated Steatohepatitis (MASH) that is to be administered once weekly subcutaneously. DA-1726 acts as a dual agonist of GLP-1 receptors (GLP1R) and glucagon receptors (GCGR), leading to weight loss through reduced appetite and increased energy expenditure. DA-1726 has a well understood mechanism and, in pre-clinical mice models, resulted in improved weight loss compared to semaglutide (Wegovy®), a leading GLP-1 receptor agonist. Additionally, in pre-clinical mouse models, DA-1726 elicited similar weight reduction, while consuming more food, compared to tirzepatide (Zepbound®) and survodutide (a drug with the same MOA), while also preserving lean body mass and demonstrating improved lipid-lowering effects compared to survodutide. In the Phase 1 multiple ascending dose (MAD) trial in obesity, the 32 mg dose of DA-1726 demonstrated best-in-class potential for weight loss, glucose control, and waist circumference reduction.
About MetaVia
MetaVia Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. The company is currently developing DA-1726 for the treatment of obesity, and is developing vanoglipel (DA-1241) for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH). DA-1726 is a novel oxyntomodulin (OXM) analogue that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist. OXM is a naturally-occurring gut hormone that activates GLP1R and GCGR, thereby decreasing food intake while increasing energy expenditure, thus potentially resulting in superior body weight loss compared to selective GLP-1 receptor agonists such as semaglutide. In a Phase 1 multiple ascending dose (MAD) trial in obesity, DA-1726 demonstrated best-in-class potential for weight loss, glucose control, and waist reduction. Vanoglipel is a novel G-protein-coupled receptor 119 (GPR119) agonist that promotes the release of key gut peptides GLP-1, GIP, and PYY. In pre-clinical studies, vanoglipel demonstrated a positive effect on liver inflammation, lipid metabolism, weight loss, and glucose metabolism, reducing hepatic steatosis, hepatic inflammation, and liver fibrosis, while also improving glucose control. In a Phase 2a clinical study, vanoglipel demonstrated direct hepatic action in addition to its glucose lowering effects.
For more information, please visit www.metaviatx.com.
Forward Looking Statements
Certain statements in this press release may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "believes", "expects", "anticipates", "may", "will", "should", "seeks", "approximately", "potential", "intends", "projects", "plans", "estimates" or the negative of these words or other comparable terminology (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including, without limitation, those risks associated with MetaVia's history of net losses, the sufficiency of its existing cash on hand to fund operations and raising additional capital; adverse global economic conditions; MetaVia's ability to execute on its commercial strategy; the ability to obtain regulatory approval through the development steps of MetaVia's current and future product candidates; the ability to realize the benefits of the license agreement with Dong-A ST Co. Ltd., including the impact on future financial and operating results of MetaVia; the cooperation of MetaVia's contract manufacturers, clinical study partners and others involved in the development of MetaVia's current and future product candidates; potential negative interactions between MetaVia's product candidates and any other products with which they are combined for treatment; MetaVia's ability to initiate and complete clinical trials on a timely basis; MetaVia's ability to recruit subjects for its clinical trials; whether MetaVia receives results from MetaVia's clinical trials that are consistent with the results of pre-clinical and previous clinical trials; impact of costs related to the license agreement, known and unknown, including costs of any litigation or regulatory actions relating to the license agreement; the effects of changes in applicable laws, regulations or Nasdaq listing rules; the effects of changes to MetaVia's stock price; and other risks and uncertainties described in MetaVia's filings with the Securities and Exchange Commission, including MetaVia's most recent Annual Report on Form 10-K. Forward-looking statements speak only as of the date when made. MetaVia does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
Contacts:
MetaVia
Marshall H. Woodworth
Chief Financial Officer
+1-857-299-1033
marshall.woodworth@metaviatx.com
Rx Communications Group
Michael Miller
+1-917-633-6086
mmiller@rxir.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/metavia-doses-the-first-patient-in-higher-dose-phase-1-study-of-da-1726-its-glp-1-and-glucagon-dual-agonist-for-the-treatment-of-obesity-302738622.html
SOURCE MetaVia Inc.